Corona Remedies Q4FY26 PAT Surges 44% YoY

Corona Remedies held its Q4FY26 earnings call, reporting a 20.2% YoY revenue growth to INR 353 crore and a 44% YoY PAT surge to INR 45 crore.
Full-year FY26 revenue grew 17.3% to INR 1,403 crore with PAT up 33.4%, while the company declared a 100% dividend (INR 10/share).
Management provided FY27 guidance for 15%+ organic revenue growth and 20%+ PAT growth, driven by new divisions, biosimilars, and recent acquisitions.
Strategic highlights include two brands crossing INR 100 crore revenue, entry into biosimilars, and expansion into Eurasian markets following EAEU GMP certification.